Keyword: Tecentriq

Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.

The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.

Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.

Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.

Bristol-Myers Squibb’s Opdivo failed another small-cell lung cancer trial—and now, its Yervoy combination approval in the field could be in jeopardy.

Roche’s I-O rivals are hurtling toward a showdown in kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.

Tecentriq is on its way to becoming the first immuno-oncology drug with an approval in triple negative breast cancer, and that path just got shorter.

In June, Merck upstaged Roche with squamous non-small cell lung cancer data. And thanks to a new nod, it looks like it’ll beat Roche to market, too.

New data showed that Roche’s Tecentriq could help some lung cancer patients live longer. But what they didn’t show may be just as important.